Episode 1 of 3: What You Need to Know About New Targeted Therapies for AD

Course Description

In episode 1 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss what practicing clinicians need to know about newly approved oral JAK inhibitors. This activity focuses on the mechanism of action of novel targeted agents, their key safety and efficacy data, and their role in the treatment paradigm for atopic dermatitis.

Scroll to Top